NC
VRTX icon

NBW Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

NBW Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$7.1M Buy
15,939
+293
+2% +$135K 1.53% 22
2025
Q1 		$7.59M Sell
15,646
-4,592
-23% -$2.14M 1.68% 15
2024
Q4 		$8.15M Sell
20,238
-351
-2% -$163K 1.51% 25
2024
Q3 		$9.58M Buy
20,589
+240
+1% +$115K 1.81% 17
2024
Q2 		$9.54M Sell
20,349
-94
-0.5% -$40.8K 1.88% 12
2024
Q1 		$8.55M Buy
20,443
+1,011
+5% +$427K 1.75% 15
2023
Q4 		$7.91M Buy
19,432
+8,145
+72% +$3.01M 1.73% 17
2023
Q3 		$3.92M Buy
11,287
+9
+0.1% +$3.15K 0.96% 51
2023
Q2 		$3.97M Buy
11,278
+47
+0.4% +$15.8K 0.93% 52
2023
Q1 		$3.54M Buy
11,231
+309
+3% +$92.7K 0.86% 57
2022
Q4 		$3.15M Buy
+10,922
New +$3.33M 0.81% 59

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NBW Capital's VRTX Position: Q2 2025 in Review

NBW Capital increased its Vertex Pharmaceuticals (VRTX) stake by 1.9% in Q2 2025, buying an estimated $135K and bringing the position to 15,939 shares worth $7.1M. The position accounts for 1.53% of the portfolio, ranked #22.

NBW Capital first reported a position in VRTX in Q4 2022 and has held it in 11 quarters since. The position peaked at $9.58M in Q3 2024. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • NBW Capital held 15,939 shares of Vertex Pharmaceuticals worth $7.1M as of Q2 2025.
  • NBW Capital bought 293 Vertex Pharmaceuticals shares in Q2 2025, an estimated $135K.
  • Vertex Pharmaceuticals made up 1.53% of NBW Capital's portfolio in Q2 2025, its #22 holding.
  • NBW Capital first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
  • NBW Capital's Vertex Pharmaceuticals position peaked at $9.58M in Q3 2024.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on NBW Capital's 13F filing for Q2 2025, filed 13 Aug 2025.